Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry - PubMed (original) (raw)
M Isabel Lucena, Neil Kaplowitz, Beatriz García-Muņoz, Yolanda Borraz, Ketevan Pachkoria, Miren García-Cortés, M Carmen Fernández, Gloria Pelaez, Luis Rodrigo, José A Durán, Joan Costa, Ramón Planas, Anabel Barriocanal, Carlos Guarner, Manuel Romero-Gomez, Teresa Muņoz-Yagüe, Javier Salmerón, Ramón Hidalgo
Affiliations
- PMID: 17133470
- DOI: 10.1002/hep.21424
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry
Raúl J Andrade et al. Hepatology. 2006 Dec.
Abstract
A chronic adverse reaction may occur in some instances of drug-induced liver injury (DILI), even despite drug cessation. In our study, we obtained records from a Spanish registry and evaluated cases of DILI with biochemical evidence of long-term damage. Chronic outcome was defined as a persistent biochemical abnormality of hepatocellular pattern of damage more than 3 months after drug withdrawal or more than 6 months after cholestatic/mixed damage. Data on 28 patients with a chronic clinical evolution (mean follow-up 20 months) between November 1995 and October 2005 were retrieved (18 female; overall mean age 55 yr) and accounted for 5.7% of total idiosyncratic DILI cases (n = 493) submitted to the registry. The main drug classes were cardiovascular and central nervous system (28.5% and 25%, respectively), which, in contrast, represented only 9.8% and 13%, respectively, of all DILI cases. The most frequent causative drugs were amoxicillin-clavulanate (4 of 69 cases), bentazepam (3 of 7 cases), atorvastatin (2 of 7 cases), and captopril (2 of 5 cases). Patients with cholestatic/mixed injury (18 of 194 cases [9%]) were more prone to chronicity than patients with hepatocellular injury (10 of 240 cases; P < .031). In the case of chronic hepatocellular injury, 3 patients progressed to cirrhosis and 2 to chronic hepatitis. In the cholestatic/mixed group, liver biopsy indicated cirrhosis in 1 patient and ductal lesions in 3 patients. In conclusion, cholestatic/mixed type of damage is more prone to become chronic while, in the hepatocellular pattern, the severity is greater. Cardiovascular and central nervous system drugs are the main groups leading to chronic liver damage.
Comment in
- How common is chronic liver disease from acute drug-induced liver injury?
Hanje AJ, Chalasani N. Hanje AJ, et al. Gastroenterology. 2007 May;132(5):2067-8; discussion 2068-9. doi: 10.1053/j.gastro.2007.03.097. Gastroenterology. 2007. PMID: 17484903 No abstract available.
Similar articles
- Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.
Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R; Spanish Group for the Study of Drug-Induced Liver Disease. Andrade RJ, et al. Gastroenterology. 2005 Aug;129(2):512-21. doi: 10.1016/j.gastro.2005.05.006. Gastroenterology. 2005. PMID: 16083708 - Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain.
Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, Villar M, Rodrigo L, Romero-Gomez M, Planas R, Barriocanal A, Costa J, Guarner C, Blanco S, Navarro JM, Pons F, Castiella A, Avila S; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)). Lucena MI, et al. Hepatology. 2006 Oct;44(4):850-6. doi: 10.1002/hep.21324. Hepatology. 2006. PMID: 17006920 - Drug-induced liver injury.
Leise MD, Poterucha JJ, Talwalkar JA. Leise MD, et al. Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Mayo Clin Proc. 2014. PMID: 24388027 Review. - Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
Björnsson E, Jacobsen EI, Kalaitzakis E. Björnsson E, et al. J Hepatol. 2012 Feb;56(2):374-80. doi: 10.1016/j.jhep.2011.07.023. Epub 2011 Sep 1. J Hepatol. 2012. PMID: 21889469 - Idiosyncratic drug-induced liver injury: an overview.
Hussaini SH, Farrington EA. Hussaini SH, et al. Expert Opin Drug Saf. 2007 Nov;6(6):673-84. doi: 10.1517/14740338.6.6.673. Expert Opin Drug Saf. 2007. PMID: 17967156 Review.
Cited by
- The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome.
Naseralallah LM, Aboujabal BA, Geryo NM, Al Boinin A, Al Hattab F, Akbar R, Umer W, Abdul Jabbar L, Danjuma MI. Naseralallah LM, et al. PLoS One. 2022 Sep 1;17(9):e0268705. doi: 10.1371/journal.pone.0268705. eCollection 2022. PLoS One. 2022. PMID: 36048762 Free PMC article. - Translating new knowledge on drug-induced liver injury into clinical practice.
Hernandez N, Pontet Y, Bessone F. Hernandez N, et al. Frontline Gastroenterol. 2019 Aug 30;11(4):303-310. doi: 10.1136/flgastro-2018-101120. eCollection 2020. Frontline Gastroenterol. 2019. PMID: 32587673 Free PMC article. Review. - Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.
Deng X, Luyendyk JP, Ganey PE, Roth RA. Deng X, et al. Pharmacol Rev. 2009 Sep;61(3):262-82. doi: 10.1124/pr.109.001727. Pharmacol Rev. 2009. PMID: 19805476 Free PMC article. Review. - Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.
Sarges P, Steinberg JM, Lewis JH. Sarges P, et al. Drug Saf. 2016 Sep;39(9):801-21. doi: 10.1007/s40264-016-0427-8. Drug Saf. 2016. PMID: 27142208 Review. - Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
Teschke R, Danan G. Teschke R, et al. Medicines (Basel). 2020 Sep 29;7(10):62. doi: 10.3390/medicines7100062. Medicines (Basel). 2020. PMID: 33003400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical